Ticker > Company >

Mankind Pharma share price

Mankind Pharma Ltd.

NSE: MANKIND BSE: 543904 SECTOR: Pharmaceuticals & Drugs  1.55 L   459   111

2629.10
+66.80 (2.61%)
BSE: 04 Aug 04:01 PM

Price Summary

Today's High

₹ 2635

Today's Low

₹ 2552.4

52 Week High

₹ 3050

52 Week Low

₹ 1910.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

108510.52 Cr.

Enterprise Value

115270.34 Cr.

No. of Shares

41.27 Cr.

P/E

59.82

P/B

7.23

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  363.66

CASH

305.87 Cr.

DEBT

7065.69 Cr.

Promoter Holding

72.68 %

EPS (TTM)

₹  43.95

Sales Growth

10.07%

ROE

15.52 %

ROCE

17.05%

Profit Growth

6.3 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Mankind Pharma Ltd.

Moxikind Mahacef Zenflox Cefakind Telmikind Amlokind Zolahart Overzyme Pantakind Ranidom Asthakind Combihale Nurokind Nurokind Plus Nurokind Gold Health OK Dynaglipt Glimestar Glykind-M Voglistar Unwanted-21 Days Prega News AcneStar Ring-Out Daffy Codistar Clonafit Manforce Epic Health OK Unwanted-72 AcneStar Kabz End Ring-Out Safe Kind Kaloree-1 Heal-O-Kind Calsimust Gel Multistar Liquid Calcimust Strong Liquid Nurokind-Plus Vet Injection Enerdyna Liquid Totavit Strong Powder Ceftiforce Injection Enrostrong

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.07%
3 Year8.26%
5 Year14.65%

Profit Growth

1 Year3.69%
3 Year11.87%
5 Year15.22%

ROE%

1 Year15.52%
3 Year17.75%
5 Year20.75%

ROCE %

1 Year17.05%
3 Year21.14%
5 Year25.88%

Debt/Equity

0.4841

Price to Cash Flow

46.73

Interest Cover Ratio

7.1942

CFO/PAT (5 Yr. Avg.)

1.03836759904079

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 72.68 0.00
Mar 2025 72.70 0.00
Dec 2024 72.71 0.00
Sep 2024 74.87 0.00
Jun 2024 74.87 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 21.138% over the past 3 years.
  • The Company has been maintaining an effective average operating margins of 23.8395717247582% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -4.06270000000001 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.03836759904079.
  • The company has a high promoter holding of 72.68%.

 Limitations

  • The company has shown a poor revenue growth of 8.25627937334403% for the Past 3 years.
  • The company is trading at a high PE of 59.82.
  • The company is trading at a high EV/EBITDA of 37.1592.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 2412.62 2529.74 2396.57 2126.59 2541.36
Total Expenditure 1836.58 1777.71 1655.64 1649.67 1868.29
Operating Profit 576.04 752.03 740.93 476.92 673.07
Other Income 96.04 105.76 69.82 219.32 64.22
Interest 6.63 1.92 199.47 162.25 146.7
Depreciation 91.33 85.42 87.03 105.24 96.93
Exceptional Items 0 0 0 0 0
Profit Before Tax 574.12 770.45 524.25 428.75 493.66
Tax 97.7 168.01 107.87 46.29 80.9
Profit After Tax 476.42 602.44 416.38 382.46 412.76
Adjusted EPS (Rs) 11.89 15.04 10.09 9.27 10

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 5523.18 7486.22 8127.15 8629.25 9497.8
Total Expenditure 4151.05 5647.73 6429.29 6362.36 6934.73
Operating Profit 1372.13 1838.49 1697.86 2266.89 2563.07
Other Income 154.5 203.81 162.78 270.5 493.21
Interest 8.23 47.54 28.23 16.93 372.28
Depreciation 78.19 123.33 269.58 335.26 378.01
Exceptional Items 0 0 0 0 0
Profit Before Tax 1440.21 1871.44 1562.84 2185.2 2305.99
Tax 355.83 482.01 314.58 412.57 421.74
Net Profit 1084.37 1389.42 1248.26 1876.16 1945.48
Adjusted EPS (Rs.) 27.07 34.68 31.16 44.25 45.67

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 40.06 40.06 40.06 40.06 41.26
Total Reserves 4694.21 6500.39 7743.85 9662.71 14599.01
Borrowings 0 0 0 0 4942.69
Other N/C liabilities 54.11 126.98 168.12 197.06 153.84
Current liabilities 1078.91 2271.27 1419.09 1616.56 4091.52
Total Liabilities 5867.29 8938.7 9371.12 11516.39 23828.32
Assets
Net Block 981.95 2921.3 3136.89 3546.28 3470.75
Capital WIP 165.51 355.28 437.83 134.74 191.36
Intangible WIP 0.06 31.28 56.95 74.7 16.07
Investments 1500.86 1657.08 2040.76 1975.85 15124.52
Loans & Advances 115.59 146.3 148.86 142.85 182.22
Other N/C Assets 16.04 14.45 36.1 15.12 150.09
Current Assets 3087.28 3813.01 3513.72 5626.85 4693.31
Total Assets 5867.29 8938.7 9371.12 11516.39 23828.32
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1440.21 1871.44 1562.84 2325.72 2390.36
Adjustment 96.74 -4.16 227 164.74 339.35
Changes in Assets & Liabilities -156.19 -585.61 294.21 -333.38 63.93
Tax Paid -397.38 -460.22 -285.06 -421 -471.48
Operating Cash Flow 983.38 821.44 1798.99 1736.08 2322.16
Investing Cash Flow -1127.16 -1360.27 -1040.61 -1665.19 -12178.83
Financing Cash Flow 88.87 578.63 -710.41 -4.73 9845.34
Net Cash Flow -54.91 39.81 47.96 66.16 -11.33

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 74.87 74.87 72.71 72.70 72.68
arjun juneja 2.04 2.04 1.98 1.98 1.98
chanakya juneja 0.97 0.97 0.94 0.94 0.94
eklavya juneja 0.97 0.97 0.94 0.94 0.94
mishka arora 0.74 0.74 0.72 0.72 0.72
poonam juneja 2.64 2.64 2.56 2.56 2.56
prem sheetal family trust... 15.41 15.41 14.97 14.97 14.96
puja juneja 2.88 2.88 2.80 2.80 2.79
rajeev juneja 1.62 1.62 1.58 1.58 1.57
rajeev juneja family trus... 19.95 19.95 19.37 19.37 19.37
ramesh juneja 1.71 1.71 1.66 1.66 1.66
ramesh juneja family trus... 20.81 20.80 20.20 20.20 20.20
ria chopra juneja 0.32 0.32 0.31 0.31 0.31
sheetal arora 4.81 4.81 4.67 4.67 4.67
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 25.13 25.13 27.29 27.30 27.32
axis mutual fund trustee ... - - - - 1.17
government pension fund g... - 1.11 1.54 1.52 1.63
nps trust a/c - sbi pensi... - - - - 1.59
sbi healthcare opportunit... - - - - 1.45
sbi life insurance co. lt... - - - 1.05 1.07
axis mutual fund trustee ... 1.28 - 1.06 1.29 -
nps trust- a/c sbi pensio... - - - 1.02 -
sbi large & midcap fund 1.50 - - 1.58 -
sbi nifty 500 index fund - - 1.67 - -
sbi nifty midcap 150 inde... - 1.49 - - -
tata aia life insurance c... - 1.08 - - -
hema cipef (i) limited 1.62 - - - -
icici prudential mutual f... 1.00 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit ICRA
Credit ICRA
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research Geojit

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q4FY24
Concall Q3FY25
Concall Q3FY24
Concall Q2FY24
Concall Q1FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23
Presentation Q3FY25
Presentation Q3FY24
Presentation Q2FY24
Presentation Q1FY25
Presentation Q1FY25
Presentation Q1FY25
Presentation H1FY24

Company News

Mankind Pharma Stock Price Analysis and Quick Research Report. Is Mankind Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Mankind Pharma and its performance over the period of time. Mankind Pharma stock price today is Rs 2628.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Mankind Pharma cash from the operating activity was Rs 2322.16 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Mankind Pharma has a Debt to Equity ratio of 0.4841 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Mankind Pharma , the EPS growth was 3.2052 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Mankind Pharma has OPM of 26.9859335846196 % which is a good sign for profitability.
     
  • ROE: Mankind Pharma have a average ROE of 15.5235 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Mankind Pharma is Rs 2628.9. One can use valuation calculators of ticker to know if Mankind Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Mankind Pharma
X